GlassScriptPhysician profile
Uzma Chaudhry
NPI 1013320936
$13,827.39
in general payments reported to CMS, 2019-2025
10 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $171 · 2021: $12K · 2022: $248 · 2023: $109 · 2024: $121 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,019.47 | 2021 | |
| Coloplast Corp | $700.46 | 2019-2025 | Altis |
| Medtronic, INC. | $462.06 | 2021-2025 | Interstim, Altaviva |
| Sumitomo Pharma America, INC. | $196.62 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $170.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Astellas Pharma US INC | $61.96 | 2022-2023 | Myrbetriq, Veozah |
| Boston Scientific Corporation | $54.13 | 2025 | Axonics |
| Medtronic USA, INC. | $25.35 | 2019-2020 | |
| Therapeuticsmd, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.